In cell-based assays, entecavir had 8- to 30-fold less inhibition of replication
of HBV containing lamivudine resistance mutations rtL180M and/or rtM204V/I than
of wild-type virus.
在基于细胞的分析中,恩替卡韦对复制的抑制作用降低了8到30倍在HBV含有拉米夫定耐药突变的 rtL180M和/或rtM204V / I 相比于 HBV野生型病毒.
因此,对拉米夫定耐药的患者,恩替卡韦的推荐剂量为1mg, 增加疗效.